Deferred Revenue

12 Months Ended

Dec. 31, 2017

Deferred Revenue Disclosure [Abstract]

Deferred Revenue

Deferred Revenue

Deferred revenue consists of the following:

	As of December 31,
	2017		2016
Current portion:
Received or receivable from Sanofi (see Note 3a)	$	177,746	$	115,267
Received or receivable from Bayer (see Note 3b)	39,000		31,084
Received or receivable from MTPC (see Note 3c)	14,027		9,188
Received or receivable from Teva (see Note 3d)	43,535		43,122
Received for technology license agreement (see Note 3h)	10,280		23,572
Other	35,550		9,431
	$	320,138	$	231,664
Long-term portion:
Received or receivable from Sanofi (see Note 3a)	$	379,936	$	503,474
Received or receivable from Bayer (see Note 3b)	29,734		77,028
Received or receivable from MTPC (see Note 3c)	56,106		45,940
Received or receivable from Teva (see Note 3d)	153,823		194,050
Received for technology license agreement (see Note 3h)	—		10,280
Other	9,600		—
	$	629,199	$	830,772